Clinical trials: Endothelial Injury

Sickle Cell Disease

TRF-1101 Assessment in Sickle Cell Disease

• Terminated
• Age: 18 years and older
• Phase 1/2

This study is designed to assess the safety, tolerability, and activity of TRF-1101 on microvascular blood flow, vascular endothelial injury, and vasoocclusive pain associated with sickle cell disease.

Trial name

NCT00773890

Testing

TRF-1101

Where

6 sites in United States

Volunteers

80 people

Sponsor

TRF Pharma, Inc